Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Optimizing chemotherapy regimens for patients with early-stage breast cancer.

Dotan E, Goldstein LJ.

Clin Breast Cancer. 2010;10 Suppl 1:E8-15. doi: 10.3816/CBC.2010.s.002. Review.

PMID:
20587409
2.

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.

Cancer Res. 2002 Aug 15;62(16):4617-22.

3.

A new look at node-negative breast cancer.

Harbeck N, Thomssen C.

Oncologist. 2010;15 Suppl 5:29-38. doi: 10.1634/theoncologist.2010-S5-29.

4.

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group.

J Natl Cancer Inst. 2001 Jun 20;93(12):913-20.

PMID:
11416112
5.

Plasminogen activator proteins tested as prognostic markers.

Nelson NJ.

J Natl Cancer Inst. 2000 Jun 7;92(11):866-8. No abstract available.

PMID:
10841817
6.

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.

Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.

Thromb Haemost. 2004 Mar;91(3):450-6. Review.

PMID:
14983219
7.
8.

Prognostic and predictive factors in early-stage breast cancer.

Cianfrocca M, Goldstein LJ.

Oncologist. 2004;9(6):606-16. Review.

9.

High levels of uPA and PAI-1 predict a good response to anthracyclines.

Pritchard KI.

Breast Cancer Res Treat. 2010 Jun;121(3):625-6. doi: 10.1007/s10549-010-0795-1. Epub 2010 Feb 23. No abstract available.

PMID:
20177965
10.

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.

Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P.

J Natl Cancer Inst. 2008 Jan 2;100(1):14-20. Epub 2007 Dec 25.

PMID:
18159072
11.

Anthracyclines and the tailoring of treatment for early breast cancer.

Piccart-Gebhart MJ.

N Engl J Med. 2006 May 18;354(20):2177-9. No abstract available.

PMID:
16707755
13.

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.

J Clin Oncol. 2006 Jun 1;24(16):2428-36. Epub 2006 May 8.

PMID:
16682728
14.
15.
16.

PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.

Lei H, Hemminki K, Johansson R, Altieri A, Enquist K, Henriksson R, Lenner P, Försti A.

Breast Cancer Res Treat. 2008 May;109(1):165-75. Epub 2007 Jul 7.

PMID:
17616807
18.

Anthracyclines in the treatment of early-stage breast cancer: ally or adversary?

Lyman GH.

Cancer Invest. 2010 Mar;28(3):217-9. doi: 10.3109/07357901003640404. No abstract available.

PMID:
20128683
19.

Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.

Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW.

Ann Surg. 1997 Dec;226(6):736-44; discussion 744-5.

20.

The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer.

Demirkan B, Ozcan MA, Glu AA, Yüksel F, Undar B, Alakavuklar M.

Clin Appl Thromb Hemost. 2006 Jan;12(1):9-14.

PMID:
16444429

Supplemental Content

Support Center